Aspiriant LLC’s Solventum SOLV Stock Holding History

Aspiriant LLC’s Portfolio SOLV Stock Details SOLV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-3,554	Closed	-$235K	–	308
2024 Q4	$235K	Sell	3,554 -151	-4%	-$10.6K	0.01%	263
2024 Q3	$258K	Sell	3,705 -156	-4%	-$9.38K	0.01%	251
2024 Q2	$204K	Buy	+3,861	New	+$234K	0.01%	272

Other funds holding SOLV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TFM

Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IFP

Independent Franchise Partners London, United Kingdom $14.3B AUM 3.49% 1-Year Est. Return

DSA

Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aspiriant LLC's SOLV Position: Q1 2025 in Review

Aspiriant LLC sold out of Solventum (SOLV) in Q1 2025, closing a stake of 3,554 shares — an estimated $235K sold.

Aspiriant LLC first reported a position in SOLV in Q2 2024 and held it in 3 quarters. The position peaked at $258K in Q3 2024. 914 funds tracked by Wall St. Rank hold SOLV as of Q1 2025.

Aspiriant LLC reported no remaining Solventum position as of Q1 2025 after selling out during the quarter.
Aspiriant LLC sold 3,554 Solventum shares in Q1 2025, an estimated $235K.
Aspiriant LLC first reported a position in Solventum in Q2 2024 and held it in 3 quarters.
Aspiriant LLC's Solventum position peaked at $258K in Q3 2024.
914 funds tracked by Wall St. Rank held Solventum as of Q1 2025.

Based on Aspiriant LLC's 13F filing for Q1 2025, filed 21 Apr 2025.